fashion
SAN FRANCISCO — In the world of drug discovery, AI progress is often measured by a single-mile marker: When will we get an AI-designed drug?
The answer remains, ambiguously, “the future,” but at STAT’s Breakthrough Summit leaders from NVIDIA and Google insisted that the impact of AI is visible today.
advertisement
Kimberly Powell, vice president of healthcare for NVIDIA, pointed to an increase in investigational new drug applications filed with the Food and Drug Administration that cite AI, as well as an uptick in early-stage readouts from clinical trials, as evidence of progress. Some of the recent readouts, Powell said, show that what’s going into Phase 1 clinical trials is more successful.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
Monthly
$39
Totals $468 per year
$39/month Get StartedTotals $468 per year
Starter
$30
for 3 months, then $39/month
$30 for 3 months Get StartedThen $39/month
Annual
$399
Save 15%
$399/year Get StartedSave 15%
11+ Users
Custom
Savings start at 25%!
Request A Quote Request A QuoteSavings start at 25%!
2-10 Users
$300
Annually per user
$300/year Get Started$300 Annually per user
View All Plans
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log InNext article： What does generative AI mean for health care? We asked experts
